Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Immunotherapy. 2022 Sep;14(13):1043-1053. doi: 10.2217/imt-2021-0232. Epub 2022 Jul 19.
To enhance the cytotoxicity of natural killer (NK) cells against prostate cancer cells via NKG2D agonist, with 4-1BB antibody and IL-27 combination. FACS was used to detect degranulation and cell surface receptors in NK cells isolated from healthy donors. Cytokine concentrations were measured using ELISA. NK-cell cytotoxicity was analyzed using Cell Counting Kit-8. NKG2D agonist, 4-1BB antibody and IL-27 combination treatment improved the activating receptor expression and IFN-γ and TNF-α secretion but decreased the suppressive receptor CD158a expression and IL-10 secretion in NK cells. The combined treatment enhanced NK-cell cytotoxicity against both PC3 and DU145 cells with concurrent enhanced STAT3 activation. 4-1BB antibody and IL-27 improved NKG2D agonist function in NK cells against prostate cancer cells.
通过 NKG2D 激动剂、4-1BB 抗体和 IL-27 的联合作用，增强自然杀伤 (NK) 细胞对前列腺癌细胞的细胞毒性。使用 FACS 检测从健康供体中分离的 NK 细胞的脱颗粒和细胞表面受体。使用 ELISA 测量细胞因子浓度。使用 Cell Counting Kit-8 分析 NK 细胞的细胞毒性。NKG2D 激动剂、4-1BB 抗体和 IL-27 的联合治疗可改善 NK 细胞的激活受体表达和 IFN-γ 和 TNF-α 分泌，但降低抑制性受体 CD158a 表达和 IL-10 分泌。联合治疗增强了 NK 细胞对 PC3 和 DU145 细胞的细胞毒性，同时增强了 STAT3 的激活。4-1BB 抗体和 IL-27 提高了 NK 细胞针对前列腺癌细胞的 NKG2D 激动剂功能。
